Brokerages Anticipate Ascendis Pharma A/S (ASND) Will Post Quarterly Sales of $160,000.00

Wall Street analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce $160,000.00 in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings, with the lowest sales estimate coming in at $30,000.00 and the highest estimate coming in at $230,000.00. Ascendis Pharma A/S posted sales of $490,000.00 in the same quarter last year, which suggests a negative year over year growth rate of 67.3%. The company is scheduled to report its next quarterly earnings results after the market closes on Wednesday, August 29th.

On average, analysts expect that Ascendis Pharma A/S will report full-year sales of $1.39 million for the current financial year, with estimates ranging from $130,000.00 to $4.00 million. For the next fiscal year, analysts forecast that the firm will post sales of $53.24 million per share, with estimates ranging from $130,000.00 to $159.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, May 30th. The biotechnology company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.38). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.30 million. Ascendis Pharma A/S had a negative net margin of 12,089.94% and a negative return on equity of 64.87%.

Several equities research analysts have recently weighed in on ASND shares. Stifel Nicolaus started coverage on Ascendis Pharma A/S in a research note on Tuesday, June 26th. They issued a “buy” rating and a $85.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $76.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, May 15th. BidaskClub raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday. Canaccord Genuity started coverage on Ascendis Pharma A/S in a research note on Tuesday, August 7th. They issued a “buy” rating and a $81.00 price target for the company. Finally, ValuEngine raised Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $72.00.

Several institutional investors have recently made changes to their positions in ASND. Atria Investments LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $212,000. Quantbot Technologies LP bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $215,000. Kovack Advisors Inc. bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $218,000. Jane Street Group LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $250,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $255,000. Institutional investors own 95.29% of the company’s stock.

Shares of ASND stock traded up $2.22 on Wednesday, hitting $76.28. The company had a trading volume of 101,300 shares, compared to its average volume of 152,352. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -17.49 and a beta of 0.67. Ascendis Pharma A/S has a twelve month low of $26.30 and a twelve month high of $76.96.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply